ORFICEF-CV 200

ORFICEF-CV 200 Tablet is a broad-spectrum antibiotic formulation from Orfit Pharmaceutical Pvt. Ltd., developed to effectively treat a wide range of bacterial infections. It combines Cefpodoxime Proxetil 200 mg, a third-generation cephalosporin antibiotic, with Potassium Clavulanate 125 mg, a beta-lactamase inhibitor that enhances antibiotic efficacy by preventing bacterial resistance. ORFICEF-CV 200 is commonly prescribed for respiratory tract infections, ear and sinus infections, throat infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial conditions. Cefpodoxime works by inhibiting bacterial cell wall synthesis, leading to bacterial death, while clavulanate protects the antibiotic from enzymatic degradation, ensuring sustained and effective antibacterial action. This combination offers reliable coverage against resistant bacterial strains, resulting in faster recovery and reduced chances of treatment failure. Manufactured under strict quality and safety standards, ORFICEF-CV 200 reflects Orfit Pharmaceutical Pvt. Ltd.’s commitment to delivering trusted, effective, and high-quality antibiotic solutions for clinical use.